Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis

NCT02253654 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02253654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02253654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
April 1, 2015
Completion date
May 25, 2016
Enrollment
216 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, erythrocyte transfusion, renal dialysis, renal insufficiency, chronic